Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

“…Importantly, the combination of <b>NT-6</b> with a small-molecule PD-L1 inhibitor NP-19 decreased tumor burden significantly (TGI% = 77.6%). …”

Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

“…Importantly, the combination of <b>NT-6</b> with a small-molecule PD-L1 inhibitor NP-19 decreased tumor burden significantly (TGI% = 77.6%). …”

Effect of the universal nuclease on various concentration of infectious intact FCoV viruses. by Finja Rausch (14352176)

“…<p>Similar time threshold with or without nuclease was detected (A), however, RT-PCR assay showed a decreased cycle threshold in nuclease pretreated samples, especially samples with lower TCID₅₀ (B). …”

Lead Optimization of Androgen Receptor-HSP27 Disrupting Agents in Glioblastoma by Yaxin Li (312731)

“…Compounds <b>4</b> and <b>6</b> exhibit IC₅₀s of 35 and 23 nM, respectively, to inhibit cell proliferation and also show significant activity to decrease the tumor growth <i>in vivo</i>.…”

Proline catabolism is required for invasive growth. by Fitz Gerald S. Silao (9384713)

Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

“…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC₅₀ values of 10^–8 M. …”

Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

“…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC₅₀ values of 10^–8 M. …”

Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

“…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC₅₀ values of 10^–8 M. …”

Fig 1 - by Alejandro Valencia (16007329)

Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA₂), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

“…Inhibition of the type 2 lysophosphatidic acid receptor (LPA₂) has recently emerged as a new potential pharmacological approach to decrease SCI-associated damage. …”

Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA₂), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

“…Inhibition of the type 2 lysophosphatidic acid receptor (LPA₂) has recently emerged as a new potential pharmacological approach to decrease SCI-associated damage. …”

The activity of LET-60ras is inhibited by oxidation of C118. by Maximilian Kramer-Drauberg (8981141)

Study flow and included patients. by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

Weaning parameters before planned extubation. by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

S1 Data - by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

Baseline characteristics of enrolled patients. by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

Kinetics of signaling molecules in pseudopods of a new or a retracting polarity axis. by Peter J. M. van Haastert (5649838)

“…The value of x, is very variable, between 4 and 20 s, but in all cases F-actin declines about 3 s before the pseudopod stops. Data are means and SEM of 10 determinations. c. Images of a cell expressing LimE-GFP (detecting F-actin) and myosin-RFP that retracts the upper pseudopod. …”

CFU trends within the <i>in silico</i> repository of simulated granuloma generated by <i>GranSim</i> after the start of infection. by Maral Budak (6680351)

The multivulva phenotype of <i>let-60rasgf</i> is sensitive to ROS. by Maximilian Kramer-Drauberg (8981141)

Primers used in ChIP-PCR. by Lorenza Cutrone (21144285)

“…Our results demonstrate that endogenous HSF2 binds to the promoters of KSHV ORF50 and EBV BZLF1 genes and shifts the bivalent chromatin state towards a more transcriptionally permissive state. …”